PMC

(A) Pooled HR for OS in patients with advanced NSCLC treated with first-line chemoimmunotherapy. (B) Pooled HR for OS in patients with advanced squamous NSCLC treated with first-line chemoimmunotherapy. (C) Pooled HR for OS in patients with advanced nonsquamous NSCLC treated with first-line chemoimmunotherapy. (D) Pooled HR for OS in patients with advanced NSCLC treated with PD-1 inhibitor (pembrolizumab) in combination with chemotherapy in the first-line setting. (E) Pooled HR for OS in patients with advanced NSCLC treated with PD-L1 inhibitor (atezolizumab) in combination with chemotherapy in the first-line setting. (F) Pooled HR for OS in PD-L1 negative patients with advanced NSCLC in the first-line setting. (G) Pooled HR for OS in PD-L1 low patients with advanced NSCLC in the first-line setting. (H) Pooled HR for OS in PD-L1 high patients with advanced NSCLC in the first-line setting.
HR: Hazard ratio; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PD-1: Programmed death receptor 1; PD-L1: Programmed death ligand 1.

One-stage IPD-pooled analysis of first-line studies (CheckMate-649, KEYNOTE-859, and ORIENT-16). (a) Overall survival in first-line studies with a CPS of <1. (b) Overall survival in first-line studies with a CPS of ≥1. (c) Overall survival in first-line studies with a CPS of <5. (d) Overall survival in first-line studies with a CPS of ≥5. (e) Progression-free survival in first-line studies with a CPS of <1. (f) Progression-free survival in first-line studies with a CPS of ≥1. (g) Progression-free survival in first-line studies with a CPS of <5. (h) Progression-free survival in first-line studies with a CPS of ≥5.

Tornado diagram showing the results of the deterministic sensitivity analysis. NN, first-line nedaplatin-based chemotherapy followed by second-line nivolumab; NT, first-line nedaplatin-based chemotherapy followed by second-line tislelizumab; ND, first-line nedaplatin-based chemotherapy followed by second-line docetaxel; CN, first-line standard chemotherapy followed by second-line nivolumab; CT, first-line standard chemotherapy followed by second-line tislelizumab; CD, first-line standard chemotherapy followed by second-line docetaxel; TID, first-line tislelizumab combined with chemotherapy followed by second-line docetaxel; CAD, first-line camrelizumab combined with chemotherapy followed by second-line docetaxel; PED, first-line pembrolizumab combined with chemotherapy followed by second-line docetaxel; SID, first-line sintilimab combined with chemotherapy followed by second-line docetaxel; SUD, first-line sugemalimab combined with chemotherapy followed by second-line docetaxel; HR, hazards rations; OS, overall survival; PFS, progression-free survival; PD, progression disease; Cam, camrelizumab; Tis, tislelizumab; Niv, nivolumab; Che, Chemotheraphy; Dox, docetaxel; BSC, best support care; IM, immunotheraphy; Sug, sugemalimab; Sin, sintilimab; Pem, pembrolizumab; CT, computed tomography; AE, adverse events.

(A) Pooled HR for PFS in patients with advanced NSCLC treated with first-line chemoimmunotherapy. (B) Pooled HR for PFS in patients with advanced squamous NSCLC treated with first-line chemoimmunotherapy. (C) Pooled HR for PFS in patients with advanced nonsquamous NSCLC treated with first-line chemoimmunotherapy. (D) Pooled HR for PFS in patients with advanced NSCLC treated with PD-1 inhibitor (nivolumab or pembrolizumab) in combination with chemotherapy in the first-line setting. (E) Pooled HR for PFS in patients with advanced NSCLC treated with PD-L1 inhibitor (atezolizumab) in combination with chemotherapy in the first-line setting. (F) Pooled HR for PFS in PD-L1 negative patients with advanced NSCLC in the first-line setting. (G) Pooled HR for PFS in PD-L1 low patients with advanced NSCLC in the first-line setting. (H) Pooled HR for PFS in PD-L1 high patients with advanced NSCLC in the first-line setting. (I) Pooled HR for PFS in patients with EGFR and ALK mutated advanced NSCLC treated with atezolizumab.
HR: Hazard ratio; NSCLC: Non-small-cell lung cancer; OS: Overall survival; PD-1: Programmed death receptor 1; PD-L1: Programmed death ligand 1; PFS: Progression-free survival.